Selecting a CRO is often treated like casting a blockbuster: choose the biggest name, assume the performance will follow.
After 25+ years inside CRO operations and working alongside sponsors, I can tell you—trial success is rarely determined by who is on the marquee. It’s driven by what happens in the execution behind the scenes.
Here are five myths I still see shaping decisions and where they lead sponsors astray.
📌Myth 1: “The biggest CRO is the safest choice.”
Scale can create capability, but it can also dilute accountability.
Large CROs offer breadth, but success depends on the specific team, governance model, and operational focus assigned to your study. I’ve seen small, specialized teams outperform global giants because they owned the outcome end-to-end.
What actually matters:
Named team experience, turnover rates, and how decisions escalate and resolve in real time.
📌Myth 2: “The lowest bid wins.”
A low bid is often just a deferred cost.
Budgets that look efficient on paper frequently unravel through change orders, recruitment delays, or under-resourced monitoring. I’ve seen “cost savings” evaporate within the first two quarters of execution.
What actually matters:
Cost realism tied to protocol complexity, enrollment assumptions grounded in data, and transparency in what is (and isn’t) fully resourced.
📌Myth 3: “We’ve worked with them before, so we’re covered.”
Past performance is context-dependent.
Teams change. Therapeutic areas differ. What worked in a Phase II oncology study may not translate to a global rare disease program with heavy regulatory nuance.
What actually matters:
Fit-for-purpose expertise: therapeutic depth, geographic strategy, and operational design aligned to this protocol, not the last one.
📌Myth 4: “Global footprint equals capability.”
Presence does not equal performance.
A CRO may list 60+ countries in their footprint, but activation timelines, site relationships, and regulatory navigation vary dramatically. I’ve seen studies stall in “covered” regions due to weak local execution.
What actually matters:
Proven country-level performance: startup cycle times, enrollment track records, and regulatory fluency where your patients actually are.
📌Myth 5: “Technology equals innovation.”
Tools do not execute trials. People and processes do.
Dashboards and platforms are only as effective as the decisions they enable. I’ve seen “digitized” trials fail due to poor data flow, unclear ownership, and lack of operational discipline.
What actually matters:
Technology that improves decision velocity and data quality. Innovation should reduce friction, not add layers.
Across hundreds of trials, the same pattern emerges:
Success is built on data integrity, realistic planning, therapeutic insight, and operational agility. This is consistently cited in industry benchmarks, but often underweighted in actual selection decisions.
The best CRO partnerships feel less like procurement and more like co-authorship, where both sides are accountable for how the story unfolds.
If you’re selecting or managing a CRO today, the question is “Who will execute when the protocol meets reality?”
If you’re challenging how you select and manage CROs, I partner with biotech and emerging sponsors to build RFPs and governance models that expose risk early and align execution to the realities of the trial. The right partner proves itself in delivery. Let’s start that conversation!
If you would rather score a CRO than assume one, the CRO Selection Scorecard is a free download.
